Generic placeholder image

Current Pharmaceutical Biotechnology

Editor-in-Chief

ISSN (Print): 1389-2010
ISSN (Online): 1873-4316

Antibody-Targeted RNase Fusion Proteins (ImmunoRNases) for Cancer Therapy

Author(s): Jurgen Krauss, Michaela A.E. Arndt, Stefan Dubel and Susanna M. Rybak

Volume 9, Issue 3, 2008

Page: [231 - 234] Pages: 4

DOI: 10.2174/138920108784567317

Price: $65

Abstract

Ribonucleases (RNases) of the superfamily A exhibit potent antineoplastic activity yet do not mediate appreciable immunogenicity or non-specific toxicity in both animal models and cancer patients. Ranpirnase (Onconase®), the first ribonuclease being evaluated as a therapeutic in humans, has progressed to phase III clinical trials in patients with unresectable mesothelioma. Conjugation of RNases to internalizing tumor-targeting monoclonal antibodies was shown to enhance specific cell killing by several orders of magnitude both in vitro and in animal models. In this review we describe the development and current status of genetically engineered 2nd generation immunoRNases as promising novel anticancer therapeutics.

Keywords: Rnase, Onconase®, immunoRNase, antibody-RNase fusion protein, immunotherapeutics

« Previous

Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy